Stock Price Movement and Market Context
On the day the stock hit Rs.384, it recorded a day change of -2.49%, underperforming the commodity chemicals sector by 0.77%. The stock has been on a downward trajectory for two consecutive sessions, losing 4.26% over this period. Notably, TruAlt Bioenergy is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained bearish momentum.
In contrast, the Sensex index, despite a negative opening and a fall of 485.14 points (-0.77%) to 83,536.95, remains 3.14% shy of its 52-week high of 86,159.02. The Sensex’s 50-day moving average is positioned above its 200-day moving average, indicating a generally positive medium-term trend for the broader market, which TruAlt Bioenergy has not mirrored.
Over the last year, TruAlt Bioenergy’s stock has delivered a flat return of 0.00%, significantly lagging the Sensex’s 7.60% gain. The stock’s 52-week high was Rs.550, highlighting the extent of the decline to the current low.
From struggle to strength! This Small Cap from Textile - Machinery is showing early turnaround signals that look promising. Position yourself now for explosive growth potential ahead!
- - Early turnaround signals
- - Explosive growth potential
- - Textile - Machinery recovery play
Position for Explosive Growth →
Financial Performance and Key Metrics
TruAlt Bioenergy’s financial indicators reveal areas of concern that have contributed to the stock’s decline. The company reported net sales of Rs.104.48 crore in the most recent quarter, marking the lowest quarterly sales figure recorded. Correspondingly, the Profit Before Depreciation, Interest and Taxes (PBDIT) stood at a negative Rs.11.79 crore, reflecting ongoing losses at the operating level.
The operating profit to interest coverage ratio for the quarter was -0.31 times, indicating that operating earnings are insufficient to cover interest expenses. This metric underscores the company’s weak long-term fundamental strength, which is further reflected in its negative Return on Capital Employed (ROCE).
Despite these challenges, the company’s debt to equity ratio remains at an average of 0 times, suggesting minimal reliance on debt financing. However, this has not translated into positive returns, as the company continues to report losses.
Valuation and Profitability Trends
On a more positive note, TruAlt Bioenergy’s ROCE is reported at 8.9%, which, combined with an enterprise value to capital employed ratio of 1.7, indicates an attractive valuation relative to its capital base. Over the past year, the company’s profits have increased by 342%, a notable improvement despite the flat stock price performance.
Nonetheless, the stock’s current Mojo Score is 20.0, with a Mojo Grade of Strong Sell as of 17 Dec 2025, reflecting the overall negative sentiment and weak financial health. This grading represents a downgrade from a previous ungraded status, signalling deteriorated fundamentals and market perception.
Is TruAlt Bioenergy your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- - Better alternatives suggested
- - Cross-sector comparison
- - Portfolio optimization tool
Sector and Industry Positioning
Operating within the commodity chemicals sector, TruAlt Bioenergy faces a competitive environment where market dynamics and pricing pressures can significantly impact financial outcomes. The company’s underperformance relative to its sector peers and the broader market index highlights the challenges it currently faces in maintaining market share and profitability.
The stock’s recent performance, including the new 52-week low, reflects these pressures and the market’s cautious stance on the company’s near-term prospects.
Summary of Key Data Points
To summarise, TruAlt Bioenergy’s stock has declined to Rs.384, its lowest level in 52 weeks and all-time low. The stock has underperformed both its sector and the Sensex index, with a flat one-year return of 0.00%. Financially, the company reported its lowest quarterly net sales of Rs.104.48 crore and a negative PBDIT of Rs.11.79 crore. The operating profit to interest coverage ratio remains negative at -0.31 times, and the company carries a Strong Sell Mojo Grade with a score of 20.0.
While valuation metrics such as ROCE and enterprise value to capital employed suggest some attractiveness, the overall financial health and market performance indicate ongoing challenges for TruAlt Bioenergy.
Unlock special upgrade rates for a limited period. Start Saving Now →
